TY - JOUR
T1 - Alzheimer's disease
T2 - The challenge of the second century
AU - Holtzman, David M.
AU - Morris, John C.
AU - Goate, Alison M.
PY - 2011/4/6
Y1 - 2011/4/6
N2 - Alzheimer's disease (AD) was first described a little more than 100 years ago. It is the most common cause of dementia with an estimated prevalence of 30 million people worldwide, a number that is expected to quadruple in 40 years. There currently is no effective treatment that delays the onset or slows the progression of AD. However, major scientific advances in the areas of genetics, biochemistry, cell biology, and neuroscience over the past 25 years have changed the way we think about AD. This review discusses some of the challenges to translating these basic molecular and cellular discoveries into clinical therapies. Current information suggests that if the disease is detected before the onset of overt symptoms, it is possible that treatments based on knowledge of underlying pathogenesis can and will be effective.
AB - Alzheimer's disease (AD) was first described a little more than 100 years ago. It is the most common cause of dementia with an estimated prevalence of 30 million people worldwide, a number that is expected to quadruple in 40 years. There currently is no effective treatment that delays the onset or slows the progression of AD. However, major scientific advances in the areas of genetics, biochemistry, cell biology, and neuroscience over the past 25 years have changed the way we think about AD. This review discusses some of the challenges to translating these basic molecular and cellular discoveries into clinical therapies. Current information suggests that if the disease is detected before the onset of overt symptoms, it is possible that treatments based on knowledge of underlying pathogenesis can and will be effective.
UR - http://www.scopus.com/inward/record.url?scp=79953854897&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.3002369
DO - 10.1126/scitranslmed.3002369
M3 - Review article
C2 - 21576255
AN - SCOPUS:79953854897
SN - 1946-6234
VL - 3
JO - Science translational medicine
JF - Science translational medicine
IS - 77
M1 - 77sr1
ER -